Barr Generic Tambocor Launch Planned For Fall Following Win In Patent Case
Executive Summary
Barr is planning to launch a generic version of 3M's Tambocor (flecainide) in the fall following a favorable court decision in a patent infringement case.
You may also be interested in...
Generic Success In Patent Cases May Slow Momentum For Waxman/Hatch Fix
A string of recent patent victories for the generic industry may take some momentum away from the drive for Waxman/Hatch reform
Generic Success In Patent Cases May Slow Momentum For Waxman/Hatch Fix
A string of recent patent victories for the generic industry may take some momentum away from the drive for Waxman/Hatch reform
Tambocor Dispute, FTC Report May Keep Generic Drugs On Congress' Agenda
A dispute between Par and Barr over generic exclusivity for flecainide reflects the continued complexities in the Waxman/Hatch process that could drive Congressional action over the next 18 months.